Recent decisions have seen the English Appeal Court criticise the decision-making process of the European Patent Office. Jacqueline Needle looks at the implications.
Recent decisions have seen the English Appeal Court criticise the decision-making process of the European Patent Office. Jacqueline Needle looks at the implications.
Introduction
Practitioners in the UK had generally been led to believe that the English courts would defer to the European Patent Office (EPO) wherever possible. However, in recent cases, the English Appeal Court has found itself, and the lower courts, to be better equipped than the EPO to deal with cases requiring an evaluation of facts. The Appeal Court has therefore declared that it will give no deference to the findings of the Technical Boards of Appeal of the EPO for cases that are ‘fact-sensitive’.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
EPO, English appeal court, gene patents, invention, biotechnology
